Henan Lingrui Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Wei Xiong

Chief Executive Officer (CEO)

CN¥1.8m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.5yrs
Participación del CEO	0.6%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Wei Xiong (39 yo)

1.5yrs

Permanencia

CN¥1,804,900

Compensación

Mr. Wei Xiong serves as General Manager and Chairman at Henan Lingrui Pharmaceutical Co. Ltd. since May 18, 2023 and served as its Managing Director.

Henan Lingrui Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.27 in 3Q 2023)

New minor risk - Share price stability

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Second quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.30 in 2Q 2023)

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 13, 2024

Dividend of CN¥0.80 announced

Full year 2023 earnings released: EPS: CN¥1.01 (vs CN¥0.84 in FY 2022)

Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.24 in 3Q 2022)

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 2Q 2022)

Now 22% undervalued

First quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.22 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.18 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥7.91

New 90-day low: CN¥8.09

New 90-day low: CN¥9.11

New 90-day low: CN¥9.28

Third quarter earnings released

New 90-day low: CN¥9.88

Earnings released

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

Permanencia

Compensación